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Abstract 
Objectives To determine trends in pregnancy-associated cancer and associations between maternal 
cancer and pregnancy outcomes. 
Design Population-based cohort study. 
Setting New South Wales, Australia, 1994–2008. 
Population 781,907 women and their 1,309,501 maternities.  
Methods Cancer and maternal information were obtained from linked cancer registry, birth and 
hospital records for the entire population. Multivariable logistic regression was used to examine 
associations between cancer risk factors and pregnancy outcomes. 
Main outcome measures Incidence of pregnancy-associated cancer (diagnosis during pregnancy or 
within 12 months of delivery), maternal morbidities, preterm birth, perinatal death, small- and large-
for-gestational-age (LGA). 
Results. 1,798 new cancer diagnoses were identified, including 499 during pregnancy and 1,299 
during postpartum. From 1994 to 2007, the crude incidence rate of pregnancy-associated cancer 
increased from 112.3 to 191.5 per 100,000 pregnancies (P < 0.001) and only 14% of the increase was 
explained by increasing maternal age. Cancer diagnosis was more common than expected in women 
aged 15–44 years (observed-to-expected ratio 1.49, 95%CI 1.42–1.56). Cancers were predominantly 
melanoma (33.3%) and breast cancer (21.0%). Women with cancer diagnosed during pregnancy had 
high rates of labour induction (28.5%), caesarean section (40.0%) and planned preterm birth (19.7%). 
Novel findings included a cancer association with multiple pregnancies (adjusted odds ratio 1.52, 
95%CI 1.13–2.05) and LGA (aOR 1.47, 95%CI 1.15–1.88). 
Conclusions Pregnancy-associated cancers have increased and the increase was only partially 
explained by increasing maternal age. Pregnancy increases women’s interaction with health services 
and the possibility for diagnosis, but may also increase the risk of cancer.  
 
Keywords: Cancer, pregnancy, incidence, cohort study, record linkage   
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Introduction 
Cancer is the second leading cause of death in women during their reproductive years. The incidence 
is generally reported to be one for every 1,000 pregnancies.1-5 Despite its rarity, the trend of women 
postponing childbearing to older age has raised concern that the incidence of cancer in pregnancy is 
likely to increase.2,3,5-8  
 
Pregnancy-associated cancer refers to instances in which the initial diagnosis of cancer is made during 
pregnancy or within 12 months of delivery.1,6,9-11 The rationale for including cancers diagnosed after 
pregnancy are: women and physicians may incorrectly attribute cancer-related symptoms to 
physiologic changes of pregnancy; reluctance to perform radiographs or invasive procedures during 
pregnancy, leading to delayed diagnosis; and less aggressive tumours are more likely to be undetected 
until after delivery.1  
 
To date, estimates of the incidence of pregnancy-associated cancer have been imprecise, for example 
malignant melanoma is reported to affect between 1 in 1,000 and 1 in 10,000 pregnancies, breast 
cancer between 1 in 3,000 and 1 in 10,000 pregnancies, and ovarian cancer between 1 in 10,000 and 1 
in 100,000 pregnancies.2,4,8 A population-based Californian study identified pregnancy-associated 
cancers with hospital data and was then repeated with linked hospital and cancer registry data. The 
study showed that cancer ascertainment from the population-based statutory cancer register produced 
more refined and reliable incidence estimates.1,9 However, the majority of published incidence 
estimates of pregnancy-associated cancer have come from case reports or small case studies and have 
relied on data collected before 2000. Consequently, questions regarding the population incidence 
remain. In addition, few studies have examined the associated pregnancy outcomes and to date the 
majority have focused on one cancer type and their sample size was small.7,10-13   
 
Accurate reporting of the incidence of pregnancy-associated cancer and the associated pregnancy 
outcomes is important for informing treatment and counselling for women. Our study had two aims: 
first to determine recent trends in incidence of pregnancy-associated cancer and the impact of 
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increasing maternal age; and second to compare risk factors and pregnancy outcomes for women with 
and without pregnancy-associated cancer. 
 
Methods 
The study population comprised 781,907 women who gave birth in New South Wales (NSW) in the 
period 1994 to 2008, which corresponded to 1,309,501 maternities and 1,329,306 infants. With a 
resident population of nearly 7 million people, NSW is the most populous State of Australia. 
Approximately one-third of all Australian births occur in NSW. 
 
Data sources 
Data were obtained from three linked NSW population databases: the Perinatal Data Collection 
(PDC), Central Cancer Registry (CCR) and Admitted Patient Data Collection (APDC). Record 
linkage was carried out by the NSW Centre for Health Record Linkage. As Australia does not have a 
unique registration number for citizens, the separate datasets were linked using probabilistic linkage 
methods.14,15 This involves a process of blocking and matching combinations of selected variables 
such as name, date of birth, address and hospital and assigning a probability weight to the match. The 
validity of the probabilistic record linkage is extremely high with less than three in 1,000 false 
positive links and less than five in 1,000 missed links.14 The researchers were provided anonymised 
data. Ethics approval for the study was obtained from the NSW Population and Health Services 
Research Ethics Committee. 
 
The PDC is a legislated population-based surveillance system that includes births of at least 20 weeks 
gestation or at least 400 grams birth weight. Information is recorded by either the midwife or medical 
practitioner providing maternity care and includes demographic, medical and obstetric information on 
the mother, as well as details of labour, delivery and condition of the neonate.  
 
The CCR is a statutory case-based registry that includes demographic, cancer diagnosis and mortality 
information for every new cancer diagnosed in NSW since 1972 with the exception of non-melanoma 
6 
 
skin cancers. Information is recorded by treating clinicians in public and private hospitals, 
departments of radiation oncology and pathology laboratories. Diagnosis, topography and 
morphology for each cancer notification are coded according to the 3rd edition of the International 
Classification of Diseases for Oncology.16 Over 90% of cancers are verified by pathology and are 
confirmed as the primary diagnosis.17 To preserve individuals’ privacy and confidentiality, only 
month and year of diagnosis are available in the registry. 
 
The APDC is a census of all hospitalisations that includes summary discharge information for every 
inpatient admission to NSW public and private hospitals. Diagnosis and procedures for each 
admission are coded according to the 10th revision of the International Classification of Disease, 
Australian Modification and the Australian Classification of Health Interventions.18  
 
PDC birth records from 1994 to 2008 were linked to the maternal cancer notifications to identify a 
cohort of women with newly diagnosed cancer during pregnancy or within twelve months of 
delivery.1,6,9-11 Linkage to the maternal birth-related hospital records was only available from 2000 to 
2008 but allowed assessment of adverse pregnancy outcomes and antenatal hospitalisations for that 
period.  
 
Study factors 
Cancers were categorised into 13 clinical groupings based on treatment categories.17 According to the 
International coding guidelines,19 stage at diagnosis was defined as the highest degree of spread that 
occurs within four months from the date of cancer diagnosis. Pregnancy-associated cancers were 
stratified depending on the time of initial diagnosis as follows: “Pregnancy” if the diagnosis was made 
between conception and delivery or “Postpartum” if the diagnosis was made within 12 months 
following delivery.  
 
Socio-demographic information included maternal age, country of birth, and based on postcode of 
residence, socio-economic status (Index of Relative Socio-economic Disadvantage)20 and 
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rural/remoteness (Accessibility/Remoteness Index for Australia).21 Pregnancy information included 
plurality and parity. Maternal factors included hypertensive disorders (chronic or gestational 
hypertension, preeclampsia or eclampsia) and diabetes (pre-existing or gestational), as well as the use 
of assisted reproductive technologies. All above information was obtained from the birth records 
except for the use of assisted reproductive technologies, which was obtained from the linked maternal 
birth-related hospital records and was only available for births occurring 2001 onwards. 
 
Pregnancy outcomes from the PDC included induction of labour, mode of delivery (spontaneous 
vaginal birth, instrumental birth and caesarean section) and place of birth. Other pregnancy outcomes 
included antenatal hospitalisation, obstetric haemorrhage (antepartum or postpartum), 
thromboembolic events (antepartum pulmonary embolism, puerperal pulmonary embolism, cerebral 
ischemia or infarction and puerperal deep vein thrombosis), sepsis (septicaemia or Group B 
streptococcal or gram negative sepsis) and severe maternal morbidity, which were obtained from 
diagnosis and procedure codes in the linked pregnancy and postpartum hospital records. Severe 
maternal morbidity was measured using a validated composite indicator relating to serious adverse 
maternal health outcomes such as transfusion, pulmonary embolism, hysterectomy and mechanical 
ventilation.22  Antenatal hospitalisation was defined as an admission prior to and without birth or an 
admission where a birth occurs with the admission date at least four days prior to the date of 
delivery.23 Perinatal outcomes included spontaneous preterm birth (<37 weeks gestation), planned 
preterm birth (induction of labour or pre-labour caesarean < 37 weeks gestation), perinatal death and 
size at birth, obtained from the birth records. Small-for-gestational-age (SGA, <10th percentile)24 was 
of interest as a potential consequence of cancer or cancer treatment. Large-for-gestational-age (LGA, 
>90th percentile)24 is a recognised risk factor for infant and childhood cancers and was pre-specified as 
potentially associated with maternal cancer. Only variables that are well and accurately reported were 
included in the analyses.25-28  
 
Statistical analyses  
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The crude incidence rates of pregnancy-associated cancer were calculated by dividing the number of 
newly diagnosed cancers during pregnancy and postpartum by the number of pregnancies, in which 
multi-fetal pregnancies were counted once. Each notification in the cancer registry is a primary 
diagnosis and more than one cancer in a pregnancy is possible. The crude rates were then standardised 
to the population in 1994 to obtain the direct age-standardised rates. All rates were expressed per 
100,000 pregnancies. 
 
To assess whether pregnancy increased the risk of cancer or cancer diagnosis, we compared the 
number of pregnancy-associated cancers with the number expected based on the population incidence 
for all women aged 15–44 years.29 We used indirect standardisation by five-year age groups for the 
five most common pregnancy-associated cancers. The observed-to-expected ratios with 95% 
confidence intervals were estimated assuming a Poisson distribution for the observed frequency.   
 
Cochran-Armitage trend tests were used to assess for a linear trend in incidence rates of pregnancy-
associated cancer, both overall and by maternal age group, for births occurring in 1994–2007. Births 
occurring in 2008 were excluded because these women did not have 12 months of postpartum data 
thereby under-ascertaining the cancer incidence. Crude associations between maternal cancer and 
each outcome were examined via cross-tabulation and chi-square tests. Multivariable logistic 
regression was used to examine both risk factors for maternal cancer and maternal cancer as a risk 
factor for adverse pregnancy outcomes. The latter were adjusted for maternal age, socio-economic 
status, plurality, parity, diabetes and hypertensive disorders to estimate the adjusted odds ratios (aOR) 
with 95% confidence intervals (95%CI). Preterm birth was further adjusted for previous preterm birth. 
Sensitivity analysis was conducted excluding women with melanoma of skin diagnosed during 
pregnancy, with no material change to the magnitude of the adjusted odds ratios (data not shown). 
Analyses were carried out in SAS, Version 9.2 (SAS Institute, Cary NC, USA).30  
 
Results 
Incidence of pregnancy-associated cancer 
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Between 1994 and 2008, a total of 1,798 pregnancy-associated cancers were identified in 1,309,501 
maternities among 781,907 women. This corresponds to an overall crude incidence of 137.3 per 
100,000 pregnancies. Figure 1 shows that from 1994 to 2007 the crude incidence rate of pregnancy-
associated cancer increased from 112.3 to 191.5 per 100,000 pregnancies (P < 0.001). During this 
period maternal age also increased; the percentage of women aged 35 years and over increased from 
13.2% to 23.6% (including women aged 40 years and over from 1.9% to 4.0%). The impact of 
increasing maternal age is demonstrated in the direct age-standardised incidence rates which fall away 
from the crude incidence rates as the years advance (Figure 1). By 2007, the age-standardised rate 
(164.0 per 100,000 pregnancies) was 14.4% lower than the crude rate (191.5 per 100,000 
pregnancies). Further, the rate per 100,000 pregnancies increased with increasing maternal age (<30 
years: 70.7 in 1994 to 105.2 in 2007, P = 0.05; 30–34 years: 168.2 to 192.8, P = 0.31; and ≥35 years: 
168.1 to 357.0, P = 0.02).  
 
A total of 1,767 women had 1,785 cancer-affected maternities and 1,798 new cancer diagnoses, 
including 499 during pregnancy and 1,299 during postpartum. Twenty nine women had two diagnoses 
of cancer and one women had three cancer diagnoses (same or different type), including 12 women 
with multiple cancers in the same pregnancy and 18 in other pregnancies. Among the study 
population from 1994 to 2008, there were 18 maternal cancer deaths in the pregnancy group and 24 in 
the postpartum group. The proportion of cancer (of any type) increased steadily as the duration of 
pregnancy advanced (Figure 2). The highest proportion of cancer occurred in the two months 
postpartum and declined slowly thereafter. The most common cancers were melanoma of skin (n = 
599, 45.7 per 100,000 pregnancies), breast cancer (n = 377, 28.8 per 100,000 pregnancies), thyroid 
and other endocrine cancers (n = 228, 17.4 per 100,000 pregnancies), gynaecological (n = 188, 14.3 
per 100,000 pregnancies) and lymphohaematopoeitic cancers (n = 151, 11.5 per 100,000 pregnancies) 
(Table 1). These cancers accounted for 85.8% of the observed counts and most (47.8%) were 
localised (e.g., melanoma of skin 65.6%) with the exception of colorectal cancer (22.6%). Forty-five 
percent of cancers during pregnancy were diagnosed before 20 weeks of gestation.  
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Comparison to cancer incidence of general female population 
There were approximately 49% more pregnancy-associated cancers than would have been expected 
based on the rates in the general female population for women aged 15–44 years from 1994–2007. 
The ratio of observed-to-expected with 95% confidence interval for all cancers was 1.49 (1.42–1.56), 
and for each of the five most common cancers: melanoma of skin 2.22 (2.05–2.41), followed by 
thyroid and other endocrine cancers 1.54 (1.35–1.75), lymphohaematopoeitic cancer 1.36 (1.15–1.59), 
breast 1.23 (1.11–1.36) and gynaecological cancers 1.20 (1.03–1.38).  
  
Maternal characteristics and risk factors 
Although increasing maternal age, Australian-born, high socio-economic status, multiparity, multiple 
pregnancy and prior diagnosis of cancer were all crude risk factors for pregnancy-associated cancer, 
only older maternal age, multiple pregnancy and prior diagnosis of cancer were retained as 
independent risk factors in the multivariable model (Table 2). Maternal age ≥40 years had the highest 
adjusted odds ratio but explained only 7.3% of cancers.   
 
Pregnancy and perinatal outcomes 
Women with cancer diagnosed during pregnancy were more likely to deliver at a tertiary hospital and 
have labour induced and pre-labour caesarean sections including preterm (Table 3 and Table S1). The 
mean gestational age at delivery was 37.7 (S.D. = 3.2) weeks for women with cancer diagnosed 
during pregnancy, 38.8 (S.D. = 2.3) weeks for women with cancer diagnosed postpartum and 39.0 
(S.D. = 2.2) weeks for women without cancer. Rates of LGA infants were increased among women 
with cancer during or after pregnancy, but perinatal death rates were similar among women with or 
without cancer (Table 3). After adjusting for other risk factors, cancer during pregnancy was 
associated with a significantly increased risk of caesarean section (aOR 2.08, 95%CI 1.70–2.54), 
planned preterm birth (aOR 10.02, 95%CI 7.90–12.72) and LGA infants (aOR 1.47, 95%CI 1.15–
1.88). A significant LGA association was observed for melanoma of skin (aOR 1.98, 95%CI 1.39–
2.83) and thyroid and other endocrine cancers (aOR 2.31, 95%CI 1.10–4.86), but not breast (aOR 
0.94, 95%CI 0.49–1.82), gynaecology (aOR 1.35, 95%CI 0.61–3.02) and lymphohaematopoeitic 
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cancers (aOR 1.13, 95%CI 0.48–2.66). The only pregnancy factor significantly associated with cancer 
after pregnancy was an increased risk of planned preterm birth (aOR 1.35, 95%CI 1.02–1.79) (Table 
S1). 
 
From 2001 to 2008, 667,019 (99.2%) birth records had a linked hospital record and Table 4 shows the 
frequency of pregnancy complications. For women with cancer diagnosed during pregnancy, there 
were large increases in pregnancy risk of thromboembolic events (aOR 10.16, 95%CI 3.77–27.37), 
sepsis (aOR 4.31, 95%CI 2.60–7.15) and severe maternal morbidity (aOR 6.88, 95%CI 4.67–10.14) 
but no significant increase in pregnancy risk for obstetric haemorrhage (aOR 1.11, 95%CI 0.75–1.64). 
For women with cancer diagnosed after pregnancy, the only significant increase in postpartum risk 
observed was for sepsis (aOR 3.31, 95%CI 2.29–4.78). 
 
Discussion 
Consistent with expectation,6,9,13 the incidence of pregnancy-associated cancer increased from 1994 to 
2007. Although maternal age was a strong risk factor for cancer, increasing maternal age explained 
only 14% of the increase. Improved diagnostic techniques, detection and increased interaction with 
health services during pregnancy might also contribute to higher incidence rates. The cancer incidence 
was higher than expected among women of reproductive age and over two-thirds of pregnancy-
associated cancers were diagnosed in the 12 months after delivery. Cancer diagnosed during or after 
pregnancy was more likely to result in planned preterm birth and maternal morbidity. 
 
Between 1994 and 2008, the overall incidence of pregnancy-associated cancer in NSW was 137.3 per 
100,000 pregnancies, which is higher than 100 per 100,000 pregnancies generally reported in 
literature.1-5 Our reported estimates for the most common types of cancer are also higher than the 
published international estimates: melanoma of skin (45.7 vs. 8.7 per 100,000), breast cancer (28.8 vs. 
19.3 per 100,000) and thyroid cancer (17.4 vs. 14.4 per 100,000), except for cervical (8.4 vs. 12.0 per 
100,000) and ovarian cancers (3.6 vs. 5.2 per 100,000).1 Our overall higher incidence is partly due to 
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the predominance of melanoma, in which Australia has the highest incidence over the world.31  
Slightly higher rates of the other cancers likely reflect our older and recent study population.  
The observation that the majority of cancers (72.2%) were diagnosed in the postpartum period has 
been noted elsewhere.1,9 Some of these cancers may have been suspected given the high rate of 
planned preterm delivery, for women whose cancer was diagnosed postpartum. Another possible 
explanation is the physiologic changes of pregnancy may make cancer more challenging to diagnose, 
leading to a delay in diagnosis.  The distribution of the timing of initial diagnosis is consistent with 
the contention that postpartum cancers are part of the cancer-in-pregnancy continuum and are 
appropriate to be included in the overall incidence.1 The steady increase in the number of cancer 
diagnoses as the duration of pregnancy advanced to peak in the two months postpartum may be 
opportunistic due to pregnancy surveillance.1  
 
The increased rate of cancer associated with pregnancy above that expected (based on the rates in the 
general female population) may be explained in twofold. First, antenatal and postnatal care, involving 
a standard protocol of history, physical examination, cervical cytology and blood pressure monitoring, 
is available for Australian women throughout and after pregnancy. On the basis of these routine care 
visits a screening effect might be expected thereby increasing the chance of detection of cancer in 
association with pregnancy. That the melanoma rate is over two times higher than expected in the 
general population is consistent with such an effect. Second, pregnancy is a proangiogenic state and it 
is plausible that the angiogenesis (driven by factors such as placental growth factor and vascular 
endothelial growth factor) required for successful placentation and pregnancy outcomes contributes to 
tumerogenesis or growth. In vitro placental growth factor increases proliferation of melanoma cells32 
and animal models demonstrate that metastasis is associated with increased expression of vascular 
endothelial growth factor receptor.33 Furthermore, women with cancer diagnosed during pregnancy 
were more likely to have multiple pregnancies, and to have large-for-gestational-age infants even after 
adjustment for pre-existing or gestational diabetes. High birth weight is an established risk factor for 
childhood cancers: Wilms’ tumour, infant and childhood leukaemia, osteosarcoma and astrocytoma34, 
and twins have increased risks of endocrine, bone and breast cancers.35,36 The postulated mechanism 
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is elevated levels of maternal hormone factors during pregnancy such as estrogens and insulin-like 
growth factor I levels or the abovementioned angiogenic factors.37 This mechanism could also 
predispose maternal cancer and deserves further investigation. There are few studies that have 
examined these associations for mothers. We found only one study that examined infant size and 
breast cancer during pregnancy, which like us, found no increased risk in infant size for breast 
cancer.37 Further, although studies of maternal cancer later in life have examined the risk for women 
who had multiple pregnancies, the findings have been contradictory and none have examined 
pregnancy-associated cancer.38 
 
The timing of cancer diagnosis has an effect on adverse pregnancy outcomes. The risks of 
thromboembolic events, sepsis and severe maternal morbidity were higher among women with cancer 
diagnosed during pregnancy. Among postpartum cancers, we only demonstrated a significant risk of 
sepsis. This is consistent with the fact that these women are more prone to infections and malignancy-
related immune-suppression, or may have had cancer treatments prior to delivery. The higher rate of 
caesarean delivery is likely to reflect the standard management plan of certain types of cancer (e.g., 
cervical cancer) in pregnant women.9 Higher rates of planned preterm delivery, to allow postpartum 
initiation of cancer treatment, has been previously reported to be common for women with cancer in 
pregnancy.9 The timing of obstetric delivery is a controversial issue surrounding the management of 
cancer associated with pregnancy. It has been reported that deliberate delay in treatment is not 
associated with poor survivorship for pregnant women with early stage cancer,5 and therefore early 
elective delivery should be carefully considered to ensure the best outcomes for the mother and 
neonate. However, this general finding needs to be assessed by cancer type. 
 
Our findings of higher risks of blood transfusion, caesarean delivery and premature birth are 
consistent with the findings of the population-based Californian studies of pregnancy-associated 
cancer.9 Similar results have also been reported from cancer registry studies on breast, cervical and 
colorectal cancers independently.7,10,11 These studies had methodological limitations, however. The 
Californian studies have assessed pregnancy outcomes solely based on hospitalisation records, in 
14 
 
which gestational age and perinatal death are poorly ascertained. Consequently, size at birth was 
defined by birth weight which does not differentiate size and maturity. Other limitations included 
restriction to a specific cancer type resulting in small sample sizes and no adjustment for socio-
economic status and maternal clinical conditions (hypertensive disorders and diabetes) in assessing 
pregnancy outcomes. 
 
The strength of our study is the population-based incidence and outcomes of cancer associated with 
pregnancy derived from large, validated and contemporary data sources. Importantly, there is a 
complete registration of cancers and births in statutory data collections in NSW. The linkage to cancer 
registry dating back to 1972 provided the opportunity to assess history of cancer as a risk factor for 
pregnancy-associated cancer. However, several limitations of our study warrant consideration. Since 
early pregnancy loss (spontaneous and therapeutic abortion) was not registered in the birth data, the 
number of pregnancy-associated cancers will be somewhat underestimated and the average gestational 
age at diagnosis will be over-estimated. We could not examine cancer treatment, as chemotherapy and 
radiotherapy are primarily provided in outpatient clinics and are under-ascertained in the 
hospitalisation records.39 History of smoking and alcohol consumption, and maternal obesity were not 
available to provide adjustment for potential confounding of pregnancy outcomes. Finally, the exact 
date of cancer diagnosis was not available and therefore the timing of initial diagnosis may be 
misclassified to some extent.  
 
Conclusion 
In summary, we found a recent increase in pregnancy-associated cancers, such that by 2007 for every 
10,000 pregnancies in Australia 19 women will have an associated cancer diagnosis. Our study 
provides contemporary cancer incidence rates by cancer type and informs women and clinicians about 
the pregnancy outcomes of cancer in pregnancy.  
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Table 1 The number and crude incidence rate of pregnancy-associated cancer, by the timing of initial diagnosis and 
clinical group of cancer, NSW, 1994–2008 
          
 
Pregnancy Postpartum All 
Clinical group of cancer n (rate*) <20 weeks† (%) n (rate*) n (rate*) 
Melanoma of skin 198 (15.1) 48.0 401 (30.6) 599 (45.7) 
Breast 95 (7.3) 33.7 282 (21.5) 377 (28.8) 
Thyroid and other endocrine 42 (3.2) 61.9 186 (14.2) 228 (17.4) 
Gynecological 51 (3.9) 37.3 136 (10.4) 187 (14.3) 
Cervix 24 (1.8) 50.0 86 (6.6) 110 (8.4) 
Ovary 19 (1.5) 21.1 28 (2.1) 47 (3.6) 
Other female genital organs 7 (0.5) 42.9 9 (0.7) 16 (1.2) 
Uterus and body 1 (0.1) 0.0 7 (0.5) 8 (0.6) 
Placenta 0 (0.0) 0.0 6 (0.5) 6 (0.4) 
Lymphohaematopoeitic 53 (4.0) 47.2 98 (7.5) 151 (11.5) 
Colorectal 10 (0.8) 20.0 52 (4.0) 62 (4.7) 
Neurological 12 (0.9) 50.0 33 (2.5) 45 (3.4) 
Bone and other connective tissue 8 (0.6) 50.0 26 (2.0) 34 (2.6) 
Head and Neck 9 (0.7) 55.6 21 (1.6) 30 (2.3) 
Upper gastrointestinal 6 (0.5) 16.7 24 (1.8) 30 (2.3) 
Respiratory 3 (0.2) 0.0 19 (1.5) 22 (1.7) 
Ill-defined and unknown primary sites 9 (0.7) 55.6 9 (0.7) 18 (1.4) 
Urogenital 3 (0.2) 66.7 12 (0.9) 15 (1.1) 
Total 499 (38.1) 44.7 1 299 (99.2) 1 798 (137.3) 
*Crude incidence rate per 100 000 pregnancies 
†Gestational age at diagnosis of less than 20 weeks among cancers diagnosed during pregnancy 
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Table 2 Maternal characteristics of 1 309 501 maternities among women with cancer diagnosed during pregnancy or postpartum compared to pregnant women without cancer 
Maternal characteristic 
Pregnancy Postpartum All  No cancer 
Crude OR     
(95%CI) 
Adjusted OR 
(95%CI) N = 495 N = 1 290 N = 1 785 N = 1 307 716 
n (%) n (%) n (%) n (%) 
Maternal age  
<30 years 147 (29.7) 362 (28.1)   509 (28.5)  654 593 (50.1) Reference  Reference  
30 – 34 years 172 (34.7) 505 (39.1)   677 (37.9)  413 643 (31.6) 2.10 [1.88,2.36] 2.09 [1.86,2.35] 
35 – 39 years 137 (27.7) 332 (25.7)   469 (26.3)  200 242 (15.3) 3.01 [2.66,3.42] 3.03 [2.66,3.44] 
≥40 years 39 (7.9) 91 (7.1)   130 (7.3)  38 615 (3.0) 4.33 [3.57,5.25] 4.38 [3.60,5.32] 
Missing  0 (0.0) 0 (0.0)   0 (0.0)   623 (0.0) - - 
Australian-born 
Yes 384 (77.6) 967 (75.0)   1 351 (75.7)  945 444 (72.3) 1.19 [1.07,1.33] 
Not retained No 110 (22.2) 321 (24.9)   431 (24.1)  359 634 (27.5) Reference  
Missing 1 (0.2) 2 (0.2)   3 (0.2)  2 638 (0.2) - 
Socio-economic status (IRSD) 
Lowest, 2nd–4th quintiles 362 (73.1) 1 001 (77.6)   1 368 (76.5) 1 064 664 (81.4) Reference  
Not retained Highest 5th quintile 133 (26.9) 284 (22.0)   417 (23.4)  230 856 (17.7) 1.41 [1.26,1.57] 
Missing 0 (0.0) 5 (0.4)   5 (0.3)  12 196 (0.9) - 
Remoteness (ARIA+) 
Urban 444 (89.7) 1 156 (89.6)   1 600 (89.7) 1 153 954 (88.3) Reference  
Not retained Rural 51 (10.3) 130 (10.1)   181 (10.1)  150 882 (11.5) 0.87 [0.74,1.01] 
Missing 0 (0.0) 4 (0.3)   4 (0.2)  2 880 (0.2) - 
Parity 
0 288 (58.2) 678 (52.6)   966 (54.1)  780 754 (59.7) Reference  Not retained 
≥1 207 (41.8) 612 (47.4) 819 (45.9) 526 962 (40.3) 1.26 [1.21,1.38] 
Plurality 
Singleton 484 (97.8) 1 256 (97.4)   1 740 (97.5) 1 288 370 (98.5) Reference  Reference  
Multiple pregnancy 11 (2.2) 34 (2.6)   45 (2.5)  19 346 (1.5) 1.72 [1.28,2.32] 1.52 [1.13,2.05] 
Diabetes 
Yes 21 (4.2) 87 (6.7)   108 (6.1)  56 302 (4.3) Not applicable 
No 474 (95.8) 1 203 (93.3)   1 677 (94.0) 1 251 414 (95.7) 
Hypertensive disorders 
Yes 38 (7.7) 96 (7.4)   134 (7.5)  88 130 (6.7) Not applicable 
No 457 (92.3) 1 194 (92.6)   1 651 (92.5) 1 219 586 (93.3) 
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Previous cancer (same or different type) 
Yes 7 (1.4) 23 (1.8)   30 (1.7)  4 454 (0.3) 5.00 [3.48,7.18] 3.79 [2.64,5.45] 
No  488 (98.6) 1 267 (98.2)   1 755 (98.3) 1 303 262 (99.7) Reference  Reference  
Assisted reproductive technology 
Yes 10 (2.0) 27 (2.1)   37 (2.1)  13 301 (1.0) 1.95 [1.40,2.70] Not retained 
No 485 (98.0) 1 263 (97.9)   1 748 (97.9)  1 294 415(99.0) Reference  
Stage of cancer 
In-situ 51 (10.3) 119 (9.2)   170 (9.5) 
Not applicable 
Localised 230 (46.5) 622 (48.3)   852 (47.8) 
Regionalised 96 (19.4) 256 (19.8)   352 (19.7) 
Distant 21 (4.2) 83 (6.4)   104 (5.8) 
Unknown  97 (19.6) 210 (16.3)   307 (17.2) 
IRSD, Index of Relative Socio-economic Disadvantage; ARIA+, Accessibility Index for Australia; OR, odds ratio, CI, confidence 
interval, adjusted for age, plurality and previous cancer. Two women with two cancers diagnosed during pregnancy. Three women with 
two cancers and one with three cancers diagnosed during postpartum. 
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Table 3 Outcomes of 1 309 501 maternities among women with cancer diagnosed during pregnancy or postpartum 
compared to pregnant women without cancer 
Pregnancy outcome  
Pregnancy Postpartum All  No cancer 
N = 495 N = 1 290 N = 1 785 N = 1 307 716 
n (%) n (%) n (%) n (%) 
Place of birth  
    Tertiary hospital 236 (47.7) 490 (38.0) 726 (40.7)  516 399 (39.5) 
Private hospital 121 (24.4) 350 (27.1) 471 (26.4)  272 860 (20.9) 
Public hospital 138 (27.9) 450 (34.9) 588 (32.9)  518 455 (39.6) 
Missing 0 (0.0) 0 (0.0) 0 (0.0)   2 (0.0) 
Induction of labour 
    Yes 141 (28.5) 342 (26.5) 483 (27.1) 310 017 (23.7) 
No  354 (71.5) 948 (73.5) 1 302 (72.9) 997 319 (76.3) 
Missing 0 (0.0) 0 (0.0) 0 (0.0)   383 (0.0) 
Mode of delivery 
    Spontaneous vaginal birth 253 (51.1) 794 (61.6) 1047 (58.7)  864 769 (66.1) 
Instrumental birth 44 (8.9) 131 (10.2) 175 (9.8)  137 415 (10.5) 
Caesarean section 198 (40.0) 365 (28.3) 563 (31.5) 304 741 (23.3) 
Pre-labour 138 (27.9) 230 (17.8) 368 (20.6) 170 648 (13.0) 
Intrapartum 60 (12.1) 135 (10.5) 195 (10.9) 134 093 (10.3) 
Not stated 0 (0.0) 0 (0.0) 0 (0.0)   791 (0.1) 
Preterm birth* 
    Any <37 weeks 122 (24.0) 128 (9.6) 250 (13.6)  93 045 (7.0) 
Spontaneous 22 (4.3) 68 (5.1) 90 (4.9)  57 309 (4.3) 
Planned 100 (19.7) 60 (4.5) 160 (8.7) 35 700 (2.7) 
    No 373 (76.0) 1 162(90.4) 1 535 (86.4) 1 214 671 (93.0) 
Perinatal death* 
    Yes 5 (1.0) 8 (0.6) 13 (0.7)  12 019 (0.9) 
No 502 (99.0) 1 315 (99.2) 1817 (99.2) 1 314 537 (99.0) 
Missing 0 (0.0) 2 (0.2) 2 (0.1)   918 (0.1) 
Birth weight percentiles* 
    <10th  54 (10.7) 136 (10.3) 190 (10.4)  133 674 (10.1) 
10th–90th 372 (73.6) 1016 (76.7) 1 389 (75.8) 1 043 541 (78.6) 
>90th 75 (14.8) 165 (12.5) 240 (13.1)  136 415 (10.3) 
Missing 5 (1.0) 8 (0.6) 13 (0.7)  13 844 (1.0) 
*Based on number of neonates: 507 where cancer was diagnosed during pregnancy,  
 1 325 where cancer was diagnosed postpartum and 1 327 474 where no cancer 
 was diagnosed.  
     Two women with two cancers diagnosed during pregnancy. Three women with two cancers   
 and one with three cancers diagnosed during postpartum. 
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Table 4 Outcomes of 679 736 maternities among women with cancer diagnosed during pregnancy or postpartum 
compared to pregnant women without cancer  
Pregnancy outcome  
Pregnancy Postpartum All  No cancer 
N = 287 N = 702 N = 989 N = 678 747 
n (%) n (%) n (%) n (%) 
Number of antenatal admissions 
    0 102 (35.5) 496 (70.7) 598 (60.5)  512 141 (74.5) 
1 97 (33.8) 147 (20.9) 244 (24.7)  113 698 (16.8) 
≥2 88 (30.7) 59 (8.4) 147 (14.9)  52 908 (8.7) 
Obstetric haemorrhage 
        Yes 28 (9.8) 76 (10.8) 104 (10.5)  60 022 (8.8) 
No 259 (90.2) 626 (89.2) 885 (89.5)  618 725 (91.2) 
Thromboembolic events 
    Yes 4 (1.4) 2 (0.3) 6 (0.6)   878 (0.1) 
No 283 (98.6) 700 (99.7) 983 (99.4)  677 869 (99.9) 
Sepsis  
    Yes 16 (5.6) 30 (4.3) 46 (4.7)  9 391 (1.4) 
No 271 (94.4) 672 (95.7) 943 (95.3) 669 356 (98.6) 
Severe maternal morbidity  
    Yes 29 (10.1) 13 (1.9) 42 (4.2)  10 672 (1.6) 
No 258 (89.9) 689 (98.1) 947 (95.8)  668 075 (98.4) 
 Data available from May 2001 onwards. 
 Two women with two cancers diagnosed during pregnancy. Three women with two cancers   
 and one with three cancers diagnosed during postpartum. 
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Figure 1 Crude and direct age-standardised incidence rates of pregnancy-associated cancer, NSW, 
1994–2007 
 
 
Figure 2 Timing of pregnancy-associated cancer diagnosis, NSW, 1994–2008 
  
